ALLMedicine™ Narcolepsy Center
Research & Reviews 1,341 results
https://clinicaltrials.gov/ct2/show/NCT04794491
Jun 24th, 2022 - The rationale for the interventional, open-label, single-arm design of JZP258-401 is to evaluate the clinical experience in participants with narcolepsy transitioning treatment from Xyrem to XYWAV.
https://doi.org/10.5664/jcsm.10134
Journal of Clinical Sleep Medicine : JCSM : Official Publ... Mahamid A, Bornstein RJ et. al.
Jun 24th, 2022 - Narcolepsy is a rare condition in Israel. Currently, the incidence of narcolepsy following SARS-CoV-2 vaccination in Israel is unknown. We are reporting a case report of a 51-year-old female of Ashkenazi Jewish descent who was evaluated for compla...
https://doi.org/10.1136/bmj.n1435
BMJ (Clinical Research Ed.); Li X, Ostropolets A et. al.
Jun 22nd, 2022 - To quantify the background incidence rates of 15 prespecified adverse events of special interest (AESIs) associated with covid-19 vaccines. Multinational network cohort study. Electronic health records and health claims data from eight countries: ...
https://clinicaltrials.gov/ct2/show/NCT04026958
Jun 21st, 2022 - Excessive daytime sleepiness and long sleep durations are common features of many neurologic disorders, including myotonic dystrophy, Parkinson's disease, and the central nervous system hypersomnia syndromes. These latter syndromes are a group of ...
https://doi.org/10.1016/j.sleep.2022.05.016
Sleep Medicine; Qu S, Wang P et. al.
Jun 20th, 2022 - To investigate the prevalence of core attention-deficit/hyperactivity disorder (ADHD) symptoms in Chinese narcolepsy type 1 (NT1) patients and to explore mood, quality of life, and executive function in narcolepsy patients with or without ADHD and...
Guidelines 1 results
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276123
Sleep Morgenthaler TI, Kapur VK et. al.
Feb 6th, 2008 - These practice parameters pertain to the treatment of hypersomnias of central origin. They serve as both an update of previous practice parameters for the therapy of narcolepsy and as the first practice parameters to address treatment of other hyp...
Drugs 215 results see all →
Clinicaltrials.gov 125 results
https://clinicaltrials.gov/ct2/show/NCT04794491
Jun 24th, 2022 - The rationale for the interventional, open-label, single-arm design of JZP258-401 is to evaluate the clinical experience in participants with narcolepsy transitioning treatment from Xyrem to XYWAV.
https://clinicaltrials.gov/ct2/show/NCT04026958
Jun 21st, 2022 - Excessive daytime sleepiness and long sleep durations are common features of many neurologic disorders, including myotonic dystrophy, Parkinson's disease, and the central nervous system hypersomnia syndromes. These latter syndromes are a group of ...
https://clinicaltrials.gov/ct2/show/NCT04451668
Jun 14th, 2022 - This study will enroll subjects with narcolepsy, either NT1 or NT2, who completed the FT218 Phase 3 REST-ON study or eligible subjects with narcolepsy currently receiving a stable dose of twice nightly sodium oxybate IR or mixed salts oxybate (reg...
https://clinicaltrials.gov/ct2/show/NCT05314556
Jun 3rd, 2022 - The aim of this pilot study is to test the benefit of behavior therapy-oriented, method-integrated psychotherapy in an outpatient group setting in patients with narcolepsy type 1. Therefore we collect and evaluate initial data on its effectiveness...
https://clinicaltrials.gov/ct2/show/NCT04923594
Jun 3rd, 2022 - This is a double-blind, randomized, placebo-controlled, multicenter trial of NLS-2 in adult patients with narcolepsy. The study will enroll approximately 60 patients and eligible patients will be treated to receive either NLS-2 or placebo for 4-we...
News 170 results
https://www.mdedge.com/dermatology/article/253900/aesthetic-dermatology/cupping-dermatology
Chloe Goldman, MD
Apr 19th, 2022 - My inspiration to write about cupping this month stems from the perception that everyone seems to be talking about it, from a facialist who suggested it for me to a coworker who swears by cupping to treat her allergies. Cupping is by no means a no.
https://www.medpagetoday.com/neurology/alzheimersdisease/94722
Sep 27th, 2021 - Treatment with methylphenidate (Ritalin), a stimulant approved for attention deficit-hyperactivity disorders (ADHD) and narcolepsy, led to a small to medium reduction in apathy in people with Alzheimer's disease, the phase III ADMET 2 trial showed...
https://www.medscape.com/viewarticle/958205
Sep 3rd, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Serious health risks were no more common in the first 3 weeks after Pfizer/BioNTech or Moderna COVID-19 vaccination compared with 22-42 days later...
https://www.mdedge.com/clinicianreviews/article/244976/sleep-medicine/future-advanced-practice-providers-apps-sleep-clinics
Loretta Colvin, NP
Aug 30th, 2021 - Loretta J. Colvin, APRN, ACNP-BC, is a Nurse Practitioner at Sleep Services, SSM Health Medical Group, specializing in the treatment of sleep disorders.
https://www.mdedge.com/psychiatry/article/244762/schizophrenia-other-psychotic-disorders/neurodegenerative-nature
Jim Kling
Aug 27th, 2021 - Schizophrenia is a complex disease caused by dysfunction in specific brain regions or circuits. In fact, schizophrenia is not a single disease but several hundred different diseases, according to Henry A.